Joseph Jimenez, the CEO of Novartis, is taking heat from all sides over his decision to charge $475,000 for a new leukemia treatment. In an exclusive interview with Forbes, he argues that the price is fair, and how he intends to charge it could shake up health care.
from Forbes Real Time //www.forbes.com/sites/matthewherper/2017/08/30/novartis-ceos-dilemma-is-475000-too-much-for-a-leukemia-breakthrough-or-is-it-not-enough/
via IFTTT
No comments:
Post a Comment